COMP <GO>
ZJYL vs LLY // 10Y YIELD & FRED MACRO BETA
JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ZJYL 0
— LLY 10
■ METRIC PARITY
LAST: $1.86 (-2.10%) • MKT CAP: $294.2M
macro-sensitivity
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZJYL VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZJYL | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 29.20% | 83.64% | -54.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 32.36% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 47.1x | 36.4x | +10.68 | LLY | /valuation <GO> |
| Free Cash Flow Yield | -1.27% | 2.30% | -3.57 | LLY | /fcf-yield <GO> |
| Operating Margin | 2.90% | 40.21% | -37.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 5.80% | 31.90% | -26.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -12.00% | 45.51% | -57.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.0 | 66.6 | -5.64 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $294.2M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZJYL REV | LLY REV | ZJYL GROSS % | LLY GROSS % | ZJYL FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.7M | $65.18B | 29.2% | 83.0% | -$3.7M | $16.81B |
| FY 2024 | $23.5M | $45.04B | 40.4% | 81.3% | -$1.4M | $8.82B |
| FY 2023 | $19.8M | $34.12B | — | 79.3% | $3.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZJYL // BETA —
LLY // BETA 0.51